Sanofi Says Its COVID-19 Vaccine Shows Better Tolerability Than Moderna Alternative in Phase 4 Trial

MT Newswires Live04-20

Sanofi (SNY) said Saturday its Nuvaxovid COVID-19 vaccine met the primary endpoint of a phase 4 trial by demonstrating a statistically lower probability of side effects compared with Moderna's (MRNA) newest mRNA vaccine.

The likelihood of experiencing at least one body-wide reaction within a week of injection was 83.6% for Nuvaxovid recipients, versus 91.6% for the competing formulation, the company said.

Severe systemic symptoms disrupting daily activities occurred in less than 10% of Nuvaxovid patients compared to one in five for the Moderna shot, while severe injection site reactions were over 75% less frequent, Sanofi said.

The trial results were presented at a medical congress in Germany, with patients receiving the protein-based shot reporting fewer disruptions to work and personal routines, it said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment